{"id":"NCT03451292","sponsor":"Grifols Therapeutics LLC","briefTitle":"Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites","officialTitle":"Prevention of Mortality With Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-24","primaryCompletion":"2024-05-21","completion":"2024-05-21","firstPosted":"2018-03-01","resultsPosted":"2025-06-06","lastUpdate":"2025-06-06"},"enrollment":410,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Decompensated Cirrhosis and Ascites"],"interventions":[{"type":"DRUG","name":"Albutein 20%","otherNames":[]},{"type":"OTHER","name":"SMT","otherNames":[]}],"arms":[{"label":"SMT + Albutein 20%","type":"EXPERIMENTAL"},{"label":"SMT","type":"ACTIVE_COMPARATOR"}],"summary":"This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in participants with decompensated cirrhosis and ascites. The study population will consist of participants being discharged after hospitalization for acute decompensation of liver cirrhosis with ascites (or with prior history of ascites requiring diuretic therapy) with or without acute-on-chronic liver failure (ACLF) at admission or during hospitalization but without ACLF at discharge.","primaryOutcome":{"measure":"Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event","timeFrame":"Up to Day 361","effectByArm":[{"arm":"SMT + Albutein 20%","deltaMin":33.5,"sd":null},{"arm":"SMT Alone","deltaMin":38.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.17"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":22},"locations":{"siteCount":66,"countries":["United States","Belgium","Bosnia and Herzegovina","Bulgaria","Canada","Denmark","France","Germany","Hungary","Italy","Poland","Serbia","Spain","United Kingdom"]},"refs":{"pmids":["30905652"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":203},"commonTop":["Anaemia","Urinary tract infection","Hyperkalaemia","Diarrhoea","Hypokalaemia"]}}